Biomarin Pharmaceutical Change To Netincome Over Time
| BMRN Stock | USD 65.42 0.54 0.83% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biomarin Pharmaceutical Performance and Biomarin Pharmaceutical Correlation. Biomarin |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.607 | Earnings Share 1.66 | Revenue Per Share 14.529 | Quarterly Revenue Growth 0.283 | Return On Assets 0.03 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change To Netincome Analysis
Compare Biomarin Pharmaceutical and related stocks such as Seagen Inc, Alnylam Pharmaceuticals, and Exelixis Change To Netincome Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNY | 3.5 M | 20.9 M | (8.2 M) | 20.9 M | (6.6 M) | 46.8 M | 72.2 M | 97.6 M | 186.3 M | 201.8 M | 156.7 M | 223.4 M | 307.7 M | 353.9 M | 371.6 M |
| EXEL | 17.1 M | 17.1 M | 17.9 M | 18.8 M | 11.5 M | 27.6 M | 39.8 M | 17.1 M | (206.1 M) | 127.7 M | 123.4 M | 195.1 M | 153.9 M | 177 M | 185.9 M |
| HALO | 5.6 M | 5.6 M | 8.4 M | 9.5 M | 15.5 M | 21.7 M | 33.3 M | 46.5 M | 35.7 M | 36.1 M | 16.4 M | (113.6 M) | 67 M | 60.3 M | 63.3 M |
| ARWR | 3.1 M | 2.2 M | 6.9 M | 14.1 M | 19.4 M | 8.1 M | 7 M | 8 M | 13.5 M | 43.4 M | 76.7 M | 125.3 M | 90.4 M | 104 M | 109.2 M |
| INCY | 29.1 M | 29.1 M | 37.9 M | 67.6 M | 62.4 M | 72.8 M | 117.4 M | 225.7 M | 174.2 M | 186.4 M | 201.5 M | (266.4 M) | 275 M | 316.3 M | 332.1 M |
| IONS | 16.5 M | 11.1 M | (4.2 M) | 9.4 M | 7 M | 61.2 M | 78.4 M | 86 M | (159.2 M) | 161.3 M | 528.8 M | 130.9 M | 103 M | 118.5 M | 87.2 M |
| APLS | 660 K | 660 K | 660 K | 660 K | 660 K | 27 M | 1.1 M | 5.4 M | 7.7 M | 37.8 M | 148.6 M | 274.3 M | 152.1 M | 174.9 M | 183.7 M |
| PCVX | (71 K) | (71 K) | (71 K) | (71 K) | (71 K) | (71 K) | (71 K) | (71 K) | (3.9 M) | (2 M) | 5.9 M | 12.2 M | 31 M | 35.6 M | 37.4 M |
| LQDA | 739.1 K | 739.1 K | 739.1 K | 739.1 K | 739.1 K | 739.1 K | 739.1 K | (6.3 M) | 1.9 M | 3.4 M | 4.1 M | 7.3 M | 10.9 M | 12.6 M | 13.2 M |
| LEGN | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | (9.9 M) | (7.8 M) | 92 M | 187.7 M | 34.2 M | 39.3 M | 55.1 M |
| TECH | 4.4 M | 5.9 M | 3.9 M | 8.5 M | 5.8 M | 14.3 M | 23.1 M | (22.1 M) | 21.1 M | 43.8 M | 94.7 M | (47.8 M) | (37.2 M) | (42.8 M) | (40.6 M) |
| MREO | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 682.8 K | 3.6 M | 6.4 M | (5 M) | 137.1 M | (16.8 M) | (16.8 M) | (19.3 M) | (18.3 M) |
| BPMC | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 5.6 M | 6.1 M | 12.5 M | 30.5 M | 54.7 M | 76 M | 95 M | 117.4 M | 135 M | 141.8 M |
| AGIO | 17.9 M | 17.9 M | 6.8 M | 6.8 M | 12 M | 32 M | 42.1 M | 47.8 M | 73.4 M | 73.4 M | 75.1 M | (39.7 M) | 49.2 M | 56.6 M | 39 M |
| DAWN | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 27.2 M | 13.3 M | 27.2 M | 31.3 M | 20.8 M |
Biomarin Pharmaceutical and related stocks such as Seagen Inc, Alnylam Pharmaceuticals, and Exelixis Change To Netincome description
My Equities
My Current Equities and Potential Positions
| Biomarin Pharmaceutical | BMRN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 65.42
Check out Biomarin Pharmaceutical Performance and Biomarin Pharmaceutical Correlation. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Biomarin Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.